ホーム › 腎臓がん（腎細胞がん） › マサチューセッツ州
マサチューセッツ州における腎臓がん（腎細胞がん）の臨床試験
マサチューセッツ州内の拠点で、腎臓がん（腎細胞がん）に関する18件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/05更新 · NCT05536141Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Lahey Clinic, Burlington
- Lahey Clinic Peabody, Peabody
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Massachusetts General Hospital Cancer Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Brigham and Women's Hospital, Boston
- Dana Farber/Mass General Brigham Cancer Care, Inc, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07227415Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Beverly Hospital, Beverly
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- 他7件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06661720A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07123090Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT06966024A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT07195682A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/09更新 · NCT03972657Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Lahey Hospital and Medical Center, Burlington
- Lahey Medical Center-Peabody, Peabody
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/11更新 · NCT07383441KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/08更新 · NCT06026410Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/04更新 · NCT04777994Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/20更新 · NCT06053658Drug Screening Using Novel IMD in Renal Cell Carcinoma
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/18更新 · NCT05700461Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/20更新 · NCT07397611Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2024/11/15更新 · NCT04787042ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。